Study to Assess Efficacy and Safety of Aclidinium Bromide and Aclidinium Bromide/Formoterol Fumarate in Stabile COPD Patients

PHASE3CompletedINTERVENTIONAL
Enrollment

1,625

Participants

Timeline

Start Date

February 2, 2017

Primary Completion Date

April 14, 2022

Study Completion Date

April 14, 2022

Conditions
COPD
Interventions
DRUG

Aclidinium bromide/formoterol Fixed-Dose Combination

Inhaled Aclidinium bromide/formoterol Fixed-Dose Combination, twice per day via Genuair

DRUG

Aclidinium bromide

Inhaled Aclidinium bromide 400 μg, twice per day via Genuair

DRUG

Formoterol Fumarate

Inhaled Formoterol Fumarate 12 μg, twice per day via Turbuhaler

DRUG

Placebo

Inhaled dose-matched placebo, twice per day via Genuair or via Turbuhaler

Trial Locations (74)

112

Research Site, Taipei

1000

Research Site, Manila

Research Site, Quezon City

1100

Research Site, Quezon City

1101

Research Site, Quezon City

1400

Research Site, Caloocan City

5000

Research Site, Iloilo City

10000

Research Site, Hanoi

14010

Research Site, Baotou

20448

Research Site, Keelung

30001

Research Site, Shanxi

40201

Research Site, Taichung

50012

Research Site, Hengyang

57002

Research Site, Mysore

61000

Research Site, Cangzhou

70000

Research Site, Ho Chi Minh City

100050

Research Site, Beijing

100097

Research Site, Beijing

102300

Research Site, Beijing

110004

Research Site, Shengyang

130021

Research Site, Changchun

133000

Research Site, Yanji

161005

Research Site, Qiqihar

200030

Research Site, Shanghai

200040

Research Site, Shanghai

200062

Research Site, Shanghai

200090

Research Site, Shanghai

200240

Research Site, Shanghai

200433

Research Site, Shanghai

201200

Research Site, Shanghai

210009

Research Site, Nanjing

214023

Research Site, Wuxi

222002

Research Site, Liangyugang

225000

Research Site, Yangzhou

230001

Research Site, Hefei

230022

Research Site, Hefei

230061

Research Site, Hefei

300050

Research Site, Tianjin

302006

Research Site, Jaipur

310003

Research Site, Hangzhou

310005

Research Site, Hangzhou

310014

Research Site, Hangzhou

317000

Research Site, Linhai

325015

Research Site, Wenzhou

330006

Research Site, Nanchang

361004

Research Site, Xiamen

380060

Research Site, Ahmedabad

410005

Research Site, Changsha

411019

Research Site, Pune

411057

Research Site, Pune

430033

Research Site, Changsha

440010

Research Site, Nagpur

440012

Research Site, Nagpur

Research Site, Pune

440019

Research Site, Nagpur

510530

Research Site, Guangzhou

518020

Research Site, Shenzhen

518053

Research Site, Shenzhen

522001

Research Site, Guntur

524001

Research Site, Zhanjiang

570311

Research Site, Haikou

610072

Research Site, Chengdu

673008

Research Site, Kozhikode

683577

Research Site, Ernākulam

688524

Research Site, Alappuzha

700000

Research Site, Ho Chi Minh City

710061

Research Site, Xi'an

750004

Research Site, Yinchuan

810007

Research Site, Xining

CN-100083

Research Site, Beijing

010017

Research Site, Hohhot

050000

Research Site, Shijiazhuang

030001

Research Site, Taiyuan

520 008

Research Site, Vijayawada

Sponsors

Lead Sponsor

Collaborators (1)

All Listed Sponsors
collaborator

Parexel

INDUSTRY

lead

AstraZeneca

INDUSTRY